Home > Portfolio > Life Sciences > METABOLON, INC.



Metabolon, Inc. is the world’s leading health technology company focused on metabolomics – an integrative, powerful tool for assessing health. Its proprietary technology is delivering biomarker discoveries, innovative diagnostic tests, breakthroughs in precision medicine, and robust partnerships in genomics-based health initiatives. Metabolon’s expertise is also accelerating research and product development across hundreds of pharmaceutical, biotechnology, consumer products, agriculture and nutrition companies, as well as academic and government organizations.

Founded in 2000 and headquartered in Research Triangle Park, North Carolina, the company’s platform is robust and has been rigorously tested and validated. Metabolon has conducted nearly 4,000 independent and collaborative studies, resulting in over 500 peer-reviewed publications.

Privately Held

The Market

Healthcare Technology – Research Services, Diagnostics and Precision Medicine

The Problem

The vast majority of diseases cannot be identified by genomics, proteomics and transcriptomics. There is growing appreciation that a combination of genetic and non-genetic factors causes complex illnesses such as diabetes, cancer, cardiovascular and neurological diseases.

Metabolon’s Solution

Metabolon has pioneered the industry’s most comprehensive global metabolomics platform, which has valuable research and clinical applications. Metabolomics is the study of chemical processes involving metabolites, the small-molecule intermediates and products of metabolism. It reflects the influences of genes, diet, lifestyle and environment to aid in understanding gene function and how diseases originate.

Metabolon has the ability to understand disease states more accurately, identify disease states earlier and with greater sensitivity, recognize treatments that may be most effective for certain populations, and  provide insight into complex biochemical processes such as drug action, toxicology and bioprocess optimization.

Metabolon uses its technology to capture the phenotype – a snapshot of the current state of health that can be used to prevent, diagnose and treat disease or improve health. The company is applying its expertise to develop and commercialize obesity-related diagnostics and support health assessment and customized treatments. A growing number of large precision medicine and next-generation sequencing (NGS) initiatives have adopted its technology as a cornerstone of their programs to link genetics and metabolic profiles to phenotypes or health states.